ArticlePigment cell & melanoma research2026
An Evolutionary Patient Journey in Uveal Melanoma.
Article in Pigment cell & melanoma research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients who receive a rare cancer diagnosis begin a diagnostic and treatment journey which is complicated by personal fear of the unknown and the reality of a scientific and clinical research community which may not have many insights, options, and definitive answers to enable long-term survival. Patients and families may initially struggle to find clinicians well-informed in the rare cancer and clinical trials of emerging therapies. Patient advocacy groups focused on specific rare cancers have established an important role and point of contact for connecting patients who share the same diagnosis, for sharing experience and perspective along the clinical journey. In this article, a patient diagnosed with uveal melanoma (UM) relates the elements of his unfolding clinical journey and the influence of a unique patient advocacy group impacting his care, decisions, personal advocacy for optimizing his own care, and quest for new and meaningful therapeutic opportunities. This journey is accompanied by a rapid evolution of prognostic analytical and clinical therapeutic research overlapping the same time frame. Key insights along the patient journey identify opportunities for clinicians to more closely observe and resolve acute and late sequelae which significantly impact quality of life after the initial diagnosis and treatment. In this article, a patient with a diagnosis of uveal melanoma recounts their diagnostic and treatment experience over 6 years. The author's insights on clinical interactions and miscues may help inform those involved in cancer research on revolutionary advances in prognostic genomics in a rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.